HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Diagnosis and treatment of chronic lead poisoning in CAPD patients.

Abstract
In order to screen for abstruse lead poisoning in continuous ambulatory peritoneal dialysis (CAPD) patients, delta-aminolevulinic acid dehydratase (ALAD) levels were measured in 18 CAPD patients, 156 patients treated with hemodialysis (HD), and 420 control patients with normal renal function (NRF). An EDTA (ethylenediamine tetraacetic acid) mobilization test was performed in patients with low levels of ALAD (< 0.40 mumol of porphobilinogen formed per milliliter of red blood cells): 1 g of EDTA was infused IV followed by 20 L of hemofiltrate in HD patients and four bags of dialysate in CAPD patients. Lead was assayed in the ultrafiltrate liquid, the bags of dialysate, and in the 24-hour urine. ALAD levels were significantly lower in CAPD and HD patients than in the NRF subjects. ALAD was significantly correlated with EDTA mobilized lead in both dialysis and NRF patients. Using the usual criteria (EDTA mobilized lead > 800 micrograms/24 hours), the rate of lead poisoning observed was similar in the two groups. These results suggest that ALAD assay followed by the EDTA mobilization test is as effective in CAPD patients as in NRF subjects to diagnose and to treat chronic abstruse lead poisoning.
AuthorsM Kessler, P Y Durand, D Hestin, J Gamberoni, J Chanliau
JournalAdvances in peritoneal dialysis. Conference on Peritoneal Dialysis (Adv Perit Dial) Vol. 9 Pg. 143-6 ( 1993) ISSN: 1197-8554 [Print] Canada
PMID8105909 (Publication Type: Journal Article)
Chemical References
  • Edetic Acid
  • Porphobilinogen Synthase
Topics
  • Chronic Disease
  • Clinical Enzyme Tests
  • Edetic Acid (therapeutic use)
  • Humans
  • Kidney Failure, Chronic (complications, therapy)
  • Lead Poisoning (diagnosis, therapy)
  • Male
  • Middle Aged
  • Peritoneal Dialysis, Continuous Ambulatory
  • Porphobilinogen Synthase (blood)
  • Renal Dialysis

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: